Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates

A second protocol defined interim analysis is planned when approximately 50% (or 55) HBeAg+ participants complete 24 weeks of the treatment period. This enrollment milestone occurred in January 2026.
Northwich Guardian

Call for Cheshire East leaders to resign over Adlington letter

A FURIOUS councillor said a House of Commons select committee hearing into new towns appears to confirm the letter sent by Cheshire East’s ...
Canada's National Observer

‘A bombshell’: doubt cast on discovery of microplastics throughout human body

High-profile studies reporting the presence of microplastics throughout the human body have been thrown into doubt by ...
WISH-TV on MSN

PFAS blood-testing pilot finds elevated levels among Indiana firefighters

Indiana firefighters logged elevated levels of potentially hazardous PFAS chemicals in their blood serum, the state has found ...

Biological Buffers Market Size to Reach USD 2.39 Billion by 2033 Owing to the Increasing Biopharmaceutical Production Globally | SNS Insider

U.S. Biological Buffers Market was Valued at USD 0.38 Billion in 2025 and is Expected to Reach USD 0.70 billion by 2033 Due to Rising Biologics and Vaccine DevelopmentAustin, Jan. 20, 2026 (GLOBE ...
Le Lézard

FireFox Gold Reports High-Grade Gold Intercept of 27.48 g/t Au over 1.75m at New Target at the Sarvi Project in Lapland, Finland

SODANKYLÄ, FINLAND / ACCESS Newswire / January 21, 2026 / FireFox Gold Corp. ("FireFox" or the "Company") is pleased to ...
Goldseiten

FireFox Gold Reports High-Grade Gold Intercept of 27.48 g/t Au over 1.75m at New Target at the Sarvi Project in Lapland

FireFox Gold is pleased to report the first results from 2025 drilling into a new target at the western end of the Company's 100%-held Sarvi gold project. Drill hole 25SA003 encountered a high-grade ...